Option chain shows key data for Aprea Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aprea Therapeutics.

Aprea Therapeutics (NASDAQ:APRE) Stock, Option Chain

Aprea Therapeutics

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

pharma lab worker ai

Biotech

Equities

News

Financing

Movers

Trading Ideas

General

APRE

FDA clearance for Aprea Therapeutics&#39; APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund clinical development and ensure company sustainability until 2026.

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

Long Ideas

Penny Stocks

Small Cap

Insider Trades

Pre-Market Outlook

Markets

ERAS

STSA

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

Offerings

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock.

What Else?

Why Aprea Therapeutics Shares Hit A New 52-Week Low Today

Aprea Therapeutics Inc

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Aprea Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/apre-stock-quote/"><strong>APRE</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Aprea Therapeutics reported earnings per share of -58 cents. This was above the analyst estimate for EPS of -64 cents.</li><li>The company reported revenue of $561,574.</li><li>This was 1,023.15% better than the analyst estimate for revenue of $50,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/apre-stock-earnings-aprea-therapeutics-for-q2-of-2024/">APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024

Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M

In a report released today, Robert Driscoll from Wedbush initiated coverage with a Buy rating on Aprea Therapeutics (APRE – Research Report) and a ...

Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) yesterday and set a price target of $16.0...

Buy Rating Justified by Aprea Therapeutics' Financial Health and Innovative Clinical Trials

Aprea Therapeutics (APRE) announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented toda...

Aprea Therapeutics presents preliminary results on APR-1051

Aprea Therapeutics ( ($APRE) ) just unveiled an announcement. Aprea Therapeutics has announced promising preliminary safety results for its WEE1 in...

Aprea Therapeutics Reports Promising Results for APR-1051 Trials

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pric...

Promising Safety and Financial Strength Propel Buy Rating for Aprea Therapeutics

Aprea Therapeutics GAAP EPS of -$0.64

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pric...

Buy Recommendation for Aprea Therapeutics Based on Promising Clinical Progress and Strategic Financial Positioning

Press Releases

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Health Care

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Comments

Aprea Therapeutics

Aprea Therapeutics (APRE) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga